Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
J. Curtis Nickel MD, FRCSC

J. Curtis Nickel MD, FRCSC

Professor, Department of Urology, Queen’s University; Canada Research Chair in Urologic Pain and Inflammation; Staff Urologist, Kingston Health Sciences Centre, Kingston, Ontario, Canada

Dr. Nickel’s clinical expertise and research covers inflammatory, infectious, pain and other benign diseases (eg benign prostatic hypeplasia) of the urinary tract. He is director of the urological chronic pain and urinary tract infection clinical research clinics in Kingston. He has over 600 publications, is on the editorial board of 6 Urology journals, editor of the AUA Update Series and Microbiome and Urologic Infections (Grand Rounds in Urology), presented in over 45 countries, funded by US NIH and Canadian CRC (CIHR). He was President of the Canadian Urological Association in 2017. He was awarded a CIHR Tier I Canada Research Chair (concurrent), AUA Distinguished Contribution Award and AUA Latimer Medal, SIU Academy Award, and was the first recipient of the SIU Mostafa Elhilali Award for contributions to International Urology Research.


Dr. Nickel reports disclosures as a consultant and from a scientific study/trial from Glaxo-Smith-Kline, Taris Biomedical, Pfizer, and Eli Lilly. He is a lecturer for Eli Lilly and Astellas, and has participated in scientific studies/trials for Johnson&Johnson and Aquinox. He is a consultant for Farr Labs, Astellas, Trillium Therapeutics, Auxillium, Ferring, and Tribute.